

## Renal cancer: From localised to metastatic disease

Live from the studio: Plenary session 04

Saturday 10 July  
11:00 - 12:30

**Location** Virtual Room 3  
**Chairs** U. Capitanio, Milan (IT)  
M-O. Grimm, Jena (DE)  
P.F.A. Mulders, Nijmegen (NL)

### Learning objectives

Renal cell cancer (RCC) is evolving rapidly with regard to molecular, diagnostic and treatment research and its implementation in clinical practice. The VHL mechanism in RCC is a good example and all its aspects will be discussed to set the scene of this session. For the small renal mass, an update will be given on different approaches and will help you to make the right decision. In larger tumours there is a shift in surgery towards more nephron sparing. A pro and con discussion on this issue will finetune your clinical practice. In the mRCC setting prospective randomised trials tried to answer the role of nephrectomy in different eras of systemic therapy. The choice can be individualised and is also dependent on new treatment possibilities.

11:00 - 11:10

**Society of Urologic Oncology (SUO) lecture The VHL kidney cancer gene: Discovery, oxygen sensing and therapy**  
W.M. Linehan, Bethesda (US)

11:10 - 11:35

**Small renal mass**  
*Moderator* A. Volpe, Novara (IT)

11:10 - 11:15

**Active surveillance**  
M.C. Mir Maresma, Barcelona (ES)

11:15 - 11:20

**Focal treatment**  
E. Barret, Paris (FR)

11:20 - 11:25

**Surgical resection**  
U. Capitanio, Milan (IT)

11:25 - 11:35

**Discussion**

11:35 - 12:00

**Case-based debate cT2 Renal cancer**  
*Moderator* J. Gómez Rivas, Madrid (ES)

11:35 - 11:40

**Case presentation**  
M. Taratkin, Moscow (RU)

11:40 - 11:45

**Partial nephrectomy whenever possible**  
C.K. Bensalah, Rennes (FR)

11:45 - 11:50

**Radical nephrectomy remains the gold standard**  
H. Zargar Shoshtari, Melbourne (AU)

11:50 - 12:00

**Panel discussion**  
*Panel* C.K. Bensalah, Rennes (FR)  
J. Gómez Rivas, Madrid (ES)  
M. Taratkin, Moscow (RU)  
H. Zargar Shoshtari, Melbourne (AU)

12:00 - 12:15

**Cytoreductive nephrectomy in the management of metastatic clear cell RCC**

12:00 - 12:05

**The ideal case: Cytoreductive nephrectomy first**  
G.N. Thalmann, Bern (CH)

## Scientific Programme - EAU21 Virtual

---

12:05 - 12:10

**Systemic treatment without or with delayed nephrectomy: When and how?**

A. Bex, London (GB)

12:10 - 12:15

**Discussion**

---

12:15 - 12:25

**State-of-the-art lecture Immunotherapy-based management of metastatic clear-cell and variant RCC: What can we achieve?**

I. Duran, Santander (ES)

---

12:25 - 12:30

**Closing remarks**